Showing 5391-5400 of 9753 results for "".
- Seaweed- and Carbonated Water-based Hydrogel Shows Promise for Treatment of Skin Woundshttps://practicaldermatology.com/news/revolutionary-seaweed-and-carbonated-water-based-hydrogel-for-treating-skin-wounds/2462184/Results from a new study suggested promise for a new seaweed- and carbonated water-based hydrogel that aims to prevent the temporary dilation of wound sites. Researchers developed a low-adhe
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Patients 9 Years and Olderhttps://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-topical-foam-03-for-the-treatment-of-seborrheic-dermatitis-in-patients-9-years-and-older/2462186/Arcutis Biotherapeutics, Inc. announced the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in those 9 years of age and older. ZORYVE foam provides rapid disease clearance and
- FDA Approves Adbry (tralokinumab-ldrm) for Treatment of Moderate-to-Severe AD in Pediatric Patients Aged 12-17 Yearshttps://practicaldermatology.com/news/fda-approval-of-tralokinumab-ldrm-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-pediatric-patients-aged-12-17-years/2462185/The US Food and Drug Administration (FDA) has expanded the approval of Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Study: Implementing a Treat-to-Target Approach Can Benefit PsA Patientshttps://practicaldermatology.com/news/implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice/2462181/A new study published in Cureus showed measuring disease activity with validated tools and treating to target (T2T) in patients with psoriatic arthritis (PsA) is crucial to improving quality of life and better disease control. The first-ever retrospective review from
- Scinai Announces Promising Results in a Psoriatic Human Skin Modelhttps://practicaldermatology.com/news/scinai-announces-promising-results-in-a-psoriatic-human-skin-model/2462180/Scinai Immunotherapeutics Ltd. announced a successful preclinical trial result for its anti-IL-17 VHH antibody (NanoAb) as a local treatment for moderate plaque psoriasis. The study, designed to evaluate the anti-inflammatory effects of NanoAbs, used proprietary induced human
- Study: Individuals With Acne Face Social and Professional Stigmahttps://practicaldermatology.com/news/study-individuals-with-acne-face-social-and-professional-stigma/2462175/Individuals with acne face social and professional stigma, and people with darker skin tones and more severe acne are disproportionately more likely to face greater stigma. These results, published in JAMA Dermatology, highlight the need to identify ways to
- Vtama Cream, 1% Continues to Wow in Scalp and Neck PsOhttps://practicaldermatology.com/news/vtama-cream-1-continues-to-wow-in-scalp-and-neck-pso/2462174/VTAMA (tapinarof) cream, 1% performed well in the treatment of psoriasis on the head and neck, according to its Phase 4, open-label trial. In the two 12-week Phase 3 pivotal studies (PSOARING 1 and 2; N=1025), VTAMA cream demonstrated a Physician Global Assessment (PGA) success rat
- Nexgel Now Owns Kenkoderm Psoriasis Skincare Linehttps://practicaldermatology.com/news/nexgel-acquires-kenkoderm-psoriasis-skincare-line/2462173/NEXGEL, Inc. now owns Kenkoderm, a privately-owned skincare product company focusing on treating the symptoms of psor
- UW's Simpson Lab Awarded $590K to Study Hailey-Hailey Diseasehttps://practicaldermatology.com/news/uws-simpson-lab-awarded-590k-to-study-hailey-hailey-disease/2462172/The Simpson Lab at the University of Washington has been awarded a three-year $590K grant by the LEO Foundation for ongoing research in Hailey-Hailey disease (HHD). Funding from this award will support Simpson Lab personnel and provide supplies for research aimed at investigating how mu